RY 172.93 -0.271% SHOP 157.86 0.7274% TD 75.22 0.2532% ENB 59.74 0.5216% BN 81.36 0.9429% TRI 234.42 0.5404% CNQ 43.01 1.2% CP 104.55 0.7225% CNR 146.44 0.7568% BMO 139.17 0.2377% BNS 77.04 -0.0649% CSU 4487.8101 0.7917% CM 91.94 -0.6054% MFC 44.04 1.1716% ATD 80.33 -0.5694% NGT 54.77 -0.635% TRP 66.14 0.532% SU 50.335 1.4819% WCN 245.2 -2.104% L 191.84 0.64%

Ceapro

Healthcare CA CZO

6.21CAD
0.12(1.97%)

Last update at 2024-06-25T13:30:00Z

Day Range

6.016.21
LowHigh

52 Week Range

0.150.73
LowHigh

Fundamentals

  • Previous Close 6.09
  • Market Cap12.92M
  • Volume600
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.43324M
  • Revenue TTM11.30M
  • Revenue Per Share TTM0.14
  • Gross Profit TTM 9.69M
  • Diluted EPS TTM-0.03

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 5.78M 2.62M 1.86M -1.13604M -0.92123M
Minority interest - - - - -
Net income 4.40M 2.84M 1.86M -1.13263M -0.31554M
Selling general administrative 3.73M 3.29M 3.39M 3.38M 3.23M
Selling and marketing expenses - - - - -
Gross profit 11.02M 9.69M 7.62M 5.45M 6.14M
Reconciled depreciation 1.91M 1.88M 1.84M 1.83M 0.58M
Ebit - 2.62M 2.35M -0.32597M 0.25M
Ebitda 7.82M 4.65M 3.87M 0.90M -0.29458M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income 5.50M 2.62M 2.35M -0.32597M 0.97M
Other operating expenses - - - - -
Interest expense 0.13M 0.15M 0.18M 0.20M 0.05M
Tax provision 1.38M -0.22369M 0.00000M -0.00341M -0.60569M
Interest income - - - - -
Net interest income -0.18497M -0.20689M -0.23016M -0.25650M -0.10305M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.22369M - -0.00341M -0.60569M
Total revenue 18.84M 17.20M 15.12M 12.88M 11.59M
Total operating expenses 13.34M 14.57M 12.77M 13.21M 10.62M
Cost of revenue 7.82M 7.51M 7.50M 7.43M 5.45M
Total other income expense net 0.46M 0.20M -0.26034M -0.55357M -1.78788M
Discontinued operations - - - - -
Net income from continuing ops 4.40M 2.84M 1.86M -1.13263M -0.31554M
Net income applicable to common shares - 2.84M 1.86M -1.13263M -0.31554M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 37.73M 30.53M 29.22M 27.27M 25.32M
Intangible assets 0.01M 0.02M 0.02M 0.02M 0.02M
Earning assets - - - - -
Other current assets - - - - -
Total liab 5.45M 3.33M 4.91M 4.96M 2.11M
Total stockholder equity 32.29M 27.20M 24.31M 22.31M 23.22M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - 16.56M 16.51M 16.40M 16.32M
Capital stock 16.69M 16.56M 16.51M 16.40M 16.32M
Retained earnings 10.88M 5.96M 3.12M 1.26M 2.39M
Other liab - - 0.87M 0.38M 0.52M
Good will - - - - 0.00000M
Other assets - 1.29M 1.56M 1.07M 1.22M
Cash 13.81M 7.78M 5.37M 1.86M 1.84M
Cash and equivalents - - - - -
Total current liabilities 2.10M 0.97M 1.39M 1.74M 1.36M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - 0.18M 0.41M
Short long term debt - - 0.07M 0.18M 0.41M
Short long term debt total - - - - -
Other stockholder equity - - - - -
Property plant equipment - 17.50M 18.59M 19.76M 17.95M
Total current assets 20.59M 11.73M 9.05M 6.41M 6.14M
Long term investments - - - - -
Net tangible assets - 27.18M 24.29M 22.29M 23.19M
Short term investments - - - - -
Net receivables 2.82M 2.14M 2.12M 3.71M 3.06M
Long term debt - - - 0.06M 0.23M
Inventory 3.76M 1.64M 1.21M 0.67M 0.71M
Accounts payable - 0.67M 1.05M 1.29M 0.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 20.86M 19.19M
Deferred long term asset charges - - - - -
Non current assets total 17.15M 18.80M 20.17M 20.86M 19.19M
Capital lease obligations 2.62M 2.65M 2.90M 3.04M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.38882M -0.79070M -0.48414M -0.19714M -1.38219M
Change to liabilities - -0.45769M -0.35814M 0.39M 0.10M
Total cashflows from investing activities - -0.79070M -0.48414M -0.19714M -1.38219M
Net borrowings - -0.33454M -0.46194M -0.68920M -0.94896M
Total cash from financing activities -0.21782M -0.30782M -0.45705M -0.67191M -0.82544M
Change to operating activities - 0.17M -0.14425M 0.15M -0.77807M
Net income 4.40M 2.84M 1.86M -1.13263M -0.31554M
Change in cash 6.03M 2.41M 3.51M 0.01M -4.32976M
Begin period cash flow 7.78M 5.37M 1.86M 1.84M 6.17M
End period cash flow 13.81M 7.78M 5.37M 1.86M 1.84M
Total cash from operating activities 6.64M 3.51M 4.45M 0.88M -2.12213M
Issuance of capital stock - - - - -
Depreciation 1.91M 1.70M 1.72M 1.82M 0.58M
Other cashflows from investing activities - -0.08680M 0.13M 0.14M -0.12709M
Dividends paid - - - - -
Change to inventory -1.43295M -0.43481M -0.54107M 0.04M 0.37M
Change to account receivables -0.72746M -0.07312M 1.64M -0.64420M -1.76893M
Sale purchase of stock - - - - -
Other cashflows from financing activities - - - - 0.12M
Change to netincome - -0.22900M 0.28M 0.25M -0.32440M
Capital expenditures 0.34M 0.71M 0.62M 0.34M 1.26M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.14119M -0.79821M 0.60M -0.06024M -2.07497M
Stock based compensation 0.09M 0.02M 0.14M 0.21M -
Other non cash items 0.13M 0.15M 0.18M 0.21M 0.06M
Free cash flow 6.30M 2.80M 3.83M 0.73M -3.37723M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CZO
Ceapro
0.12 1.97% 6.21 - - 1.14 0.43 0.35 -2.6334
NGEN
NervGen Pharma Corp
-0.11 3.67% 2.89 - - - 14.75 -4.5367
ARCH
Arch Biopartners Inc
0.02 1.13% 1.79 - - 93.45 - 53.05 -97.5918
COV
Covalon Technologies Ltd.
-0.13 3.85% 3.25 - - 3.38 4.55 3.09 2136.68
MIR
MedMira Inc
-0.01 11.11% 0.08 - - 164.76 - 180.27 -80.0318

Reports Covered

Stock Research & News

Profile

Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.

Ceapro

7824 ? 51 Avenue NW, Edmonton, AB, Canada, T6E 6W2

Key Executives

Name Title Year Born
Mr. Gilles R. Gagnon ICD.D, M.B.A., M.Sc., MBA CEO, Pres & Director 1954
Ms. Stacy Prefontaine CPA, CA CFO & Corp. Sec. NA
Dr. Bernhard Seifried Sr. Director of Research & Technology NA
Ms. Sigrun Watson Chief Revenue Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.